Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Reports Acquisition of Restricted Stock Units

Bruce Cozadd, Chairman & CEO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.

Summary

• On March 1, 2024, Bruce C Cozadd, Chairman & CEO of Jazz Pharmaceuticals, acquired 50,187 ordinary shares in the form of restricted stock units.
• These units were granted under the Issuer's 2011 Equity Incentive Plan.
• Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting.
• The restricted stock units vest in equal annual installments over four years, starting from March 5, 2024.
• 1/4th of the units will vest on the first anniversary of the vesting commencement date, with the remainder vesting in equal annual installments over the subsequent three years.
• Following the transaction, Cozadd beneficially owns 452,245 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.

Industry Context

This type of equity compensation is common for executives in publicly traded companies to align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation packages, including restricted stock units, are a standard practice among publicly traded companies like Jazz Pharmaceuticals to incentivize and retain key executives.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their leadership teams.
• The vesting schedules and amounts of these grants are typically benchmarked against industry peers and individual performance.

Stakeholder Impact

• Shareholders may view the equity grant positively as it incentivizes the CEO to drive long-term value.
• Employees may see it as a sign of stability and commitment from the company's leadership.

Key Dates